UK pharma contribution to NHS medicines bill almost £1.3 billion

16 June 2016
abpi-big-1

The Association of the British Pharmaceutical Industry (ABPI) has today published details of payment to the Department of Health under the five-year Pharmaceutical Price Regulation Scheme (PPRS).

The figures show that the companies which are voluntarily signed up to the scheme have paid £367million ($526 million) between September 2015 and March 2016, taking total payments to £1.296 billion. However, the overall spend on medicines covered by the scheme has remained flat over the past 12 months.

Measured Spend

PPRS Year 2014/15 – comprising Q4 2014 + Q1 2015

£4,117 million

PPRS Year 2015/16 – comprising Q4 2015 + Q1 2016

£4,116 million

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical